8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 7, 2026·SEC
ANI Pharmaceuticals, Inc.(ANIP)Earnings, Financials & Key Ratios
ANIP•NASDAQ
23.9× P/E·Price updated Jun 19, 2026
AboutANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.Show more
- Revenue$883M+43.8%
- EBITDA$173M+152.7%
- Net Income$78M+522.9%
- EPS (Diluted)3.32+419.2%
- Gross Margin51.01%-13.9%
- EBITDA Margin19.54%+75.8%
- Operating Margin9.2%+9569.3%
- Net Margin8.87%+394.1%
- ROE16.16%+486.7%
ANIP Key Insights
ANI Pharmaceuticals, Inc. (ANIP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 19.4% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 33.5%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ANIP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANIP Price & Volume
ANI Pharmaceuticals, Inc. (ANIP) stock price & volume — 10-year historical chart
Loading chart...
ANIP Growth Metrics
ANI Pharmaceuticals, Inc. (ANIP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.75%
5 Years33.48%
3 Years40.81%
TTM37.03%
Profit CAGR
10 Years17.68%
5 Years-
3 Years-
TTM526%
EPS CAGR
10 Years9.66%
5 Years-
3 Years-
TTM410.24%
Return on Capital
10 Years2.88%
5 Years0.24%
3 Years4.63%
Last Year7.21%
ANIP Recent Earnings
ANI Pharmaceuticals, Inc. (ANIP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$2.05+60.2%
$1.28
Rev
$237M+14.4%
$208M
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$2.33+17.1%
$1.99
Rev
$247M+6.9%
$231M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$2.04+17.2%
$1.74
Rev
$228M-1.9%
$232M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.80+30.4%
$1.38
Rev
$211M+1.2%
$209M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $2.05vs $1.28+60.2% | $237Mvs $208M+14.4% |
| Q1 2026 | Feb 27, 2026 | $2.33vs $1.99+17.1% | $247Mvs $231M+6.9% |
| Q4 2025 | Nov 7, 2025 | $2.04vs $1.74+17.2% | $228Mvs $232M-1.9% |
| Q3 2025 | Aug 8, 2025 | $1.80vs $1.38+30.4% | $211Mvs $209M+1.2% |
Based on last 12 quarters of dataView full earnings history →
ANIP Peer Comparison
ANI Pharmaceuticals, Inc. (ANIP) competitors in Complex generics and injectables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AMRX | 5.1B | 16.21 | 73.68 | 8.05% | 2.39% | 7.47% | 0.13 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 HI | 2.26B | 31.98 | 52.43 | -15.99% | 1.37% | 2.43% | 1.12 | |
 SLDB | 648.99M | 8.33 | -4.19 | -74.45% | 0.12 | |||
 VTRS | 17.9B | 15.37 | -5.12 | -2.98% | -2.04% | -1.97% | 1.00 |
Compare ANIP vs Peers
ANI Pharmaceuticals, Inc. (ANIP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANIP Income Statement
ANI Pharmaceuticals, Inc. (ANIP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 176.84M | 201.58M | 206.55M | 208.47M | 216.14M | 316.38M | 486.82M | 614.38M | 883.37M | 923.71M |
Revenue Growth % | 37.49% | 13.99% | 2.47% | 0.93% | 3.67% | 46.38% | 53.87% | 26.2% | 43.78% | 37.03% |
Cost of Goods Sold | 79.03M | 73.02M | 63.15M | 87.16M | 100.61M | 138.78M | 181.51M | 250.21M | 432.73M | 314.64M |
COGS % of Revenue | 44.69% | 36.23% | 30.58% | 41.81% | 46.55% | 43.87% | 37.29% | 40.73% | 48.99% | - |
Gross Profit | 97.81M▲ 0% | 128.55M▲ 31.4% | 143.39M▲ 11.5% | 121.32M▼ 15.4% | 115.53M▼ 4.8% | 177.6M▲ 53.7% | 305.3M▲ 71.9% | 364.17M▲ 19.3% | 450.64M▲ 23.7% | 609.07M▲ 0% |
Gross Margin % | 55.31% | 63.77% | 69.42% | 58.19% | 53.45% | 56.13% | 62.71% | 59.27% | 51.01% | 65.94% |
Gross Profit Growth % | 22.5% | 31.43% | 11.54% | -15.39% | -4.77% | 53.73% | 71.9% | 19.28% | 23.75% | - |
Operating Expenses | 68.58M | 93.19M | 127.04M | 137.33M | 155.32M | 212.88M | 258.33M | 363.58M | 369.41M | 485.46M |
OpEx % of Revenue | 38.78% | 46.23% | 61.51% | 65.88% | 71.86% | 67.29% | 53.07% | 59.18% | 41.82% | - |
Selling, General & Admin | 31.58M | 44.06M | 55.84M | 64.99M | 84.29M | 124.04M | 161.7M | 249.64M | 317.75M | 314.87M |
SG&A % of Revenue | 17.86% | 21.86% | 27.04% | 31.17% | 39% | 39.21% | 33.22% | 40.63% | 35.97% | - |
Research & Development | 9.07M | 15.39M | 19.81M | 16M | 11.37M | 22.32M | 34.29M | 44.58M | 51.66M | 51.7M |
R&D % of Revenue | 5.13% | 7.63% | 9.59% | 7.68% | 5.26% | 7.05% | 7.04% | 7.26% | 5.85% | - |
Other Operating Expenses | 55K | -550K | 51.39M | 56.35M | 59.66M | 66.52M | 62.35M | 69.36M | 0 | 2M |
Operating Income | 28.33M▲ 0% | 35.36M▲ 24.8% | 16.35M▼ 53.8% | -16.02M▼ 198.0% | -39.79M▼ 148.5% | -35.28M▲ 11.3% | 46.97M▲ 233.1% | 584K▼ 98.8% | 81.23M▲ 13809.2% | 123.61M▲ 0% |
Operating Margin % | 16.02% | 17.54% | 7.92% | -7.68% | -18.41% | -11.15% | 9.65% | 0.1% | 9.2% | 13.38% |
Operating Income Growth % | 41.09% | 24.82% | -53.76% | -197.95% | -148.46% | 11.33% | 233.13% | -98.76% | 13809.25% | - |
EBITDA | 56.26M | 69.1M | 60.96M | 28.62M | 7.46M | 24.37M | 106.76M | 68.31M | 172.65M | 213.05M |
EBITDA Margin % | 31.81% | 34.28% | 29.52% | 13.73% | 3.45% | 7.7% | 21.93% | 11.12% | 19.54% | 23.06% |
EBITDA Growth % | 32.61% | 22.83% | -11.78% | -53.05% | -73.94% | 226.72% | 338.09% | -36.01% | 152.72% | 158.55% |
D&A (Non-Cash Add-back) | 27.93M | 33.74M | 44.61M | 44.64M | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M | 89.44M |
EBIT | 29.23M | 34.81M | 16.12M | -16.51M | -44.14M | -34.61M | 46.81M | -4.61M | 115.85M | 147.51M |
Net Interest Income | -12.04M | -14.76M | -12.97M | -9.45M | -11.92M | -28.05M | -26.94M | -17.6M | -20.06M | -23.83M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.19M |
Interest Expense | 12.04M | 14.76M | 12.97M | 9.45M | 11.92M | 28.05M | 26.94M | 17.6M | 20.06M | 32.02M |
Other Income/Expense | -11.98M | -15.31M | -13.19M | -9.95M | -16.27M | -27.38M | -27.1M | -22.8M | 14.56M | -7.58M |
Pretax Income | 16.35M▲ 0% | 20.05M▲ 22.6% | 3.16M▼ 84.3% | -25.96M▼ 922.4% | -56.06M▼ 115.9% | -62.66M▼ 11.8% | 19.87M▲ 131.7% | -22.21M▼ 211.8% | 95.79M▲ 531.3% | 116.03M▲ 0% |
Pretax Margin % | 9.25% | 9.95% | 1.53% | -12.45% | -25.94% | -19.81% | 4.08% | -3.62% | 10.84% | 12.56% |
Income Tax | 17.43M | 4.56M | -2.94M | -3.41M | -13.46M | -14.77M | 1.09M | -3.69M | 17.45M | 23.88M |
Effective Tax Rate % | 106.58% | 22.73% | -93.03% | 13.15% | 24% | 23.57% | 5.5% | 16.61% | 18.22% | 20.58% |
Net Income | -1.08M▲ 0% | 15.49M▲ 1540.0% | 6.09M▼ 60.7% | -22.55M▼ 470.0% | -42.6M▼ 88.9% | -47.9M▼ 12.4% | 18.78M▲ 139.2% | -18.52M▼ 198.6% | 78.34M▲ 522.9% | 89.67M▲ 0% |
Net Margin % | -0.61% | 7.69% | 2.95% | -10.82% | -19.71% | -15.14% | 3.86% | -3.01% | 8.87% | 9.71% |
Net Income Growth % | -127.35% | 1539.96% | -60.67% | -470% | -88.94% | -12.42% | 139.21% | -198.63% | 522.94% | 526% |
Net Income (Continuing) | -1.08M | 15.49M | 6.09M | -22.55M | -42.6M | -47.9M | 18.78M | -18.52M | 78.34M | 92.15M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.09▲ 0% | 1.32▲ 1516.3% | 0.50▼ 62.1% | -1.88▼ 476.0% | -3.40▼ 80.9% | -3.05▲ 10.3% | 0.94▲ 130.8% | -1.04▼ 210.6% | 3.32▲ 419.2% | 4.16▲ 0% |
EPS Growth % | -127.41% | 1516.31% | -62.12% | -476% | -80.85% | 10.29% | 130.82% | -210.64% | 419.23% | 410.24% |
EPS (Basic) | -0.09 | 1.33 | 0.51 | -1.88 | -3.40 | -3.05 | 0.95 | -1.04 | 3.50 | - |
Diluted Shares Outstanding | 11.55M | 11.77M | 12.04M | 11.96M | 12.6M | 16.26M | 18.19M | 19.32M | 21.23M | 21.54M |
Basic Shares Outstanding | 11.55M | 11.68M | 11.84M | 11.96M | 12.6M | 16.26M | 18M | 19.32M | 20.05M | 20.91M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ANIP Balance Sheet
ANI Pharmaceuticals, Inc. (ANIP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 131.6M | 152.88M | 187.69M | 170.32M | 321.77M | 344.26M | 519.82M | 527.68M | 753.12M | 747.08M |
Cash & Short-Term Investments | 31.14M | 43.01M | 62.33M | 7.86M | 100.3M | 48.23M | 221.12M | 151.17M | 285.58M | 311.18M |
Cash Only | 31.14M | 43.01M | 62.33M | 7.86M | 100.3M | 48.23M | 221.12M | 144.86M | 285.58M | 311.18M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.31M | 0 | 0 |
Accounts Receivable | 58.79M | 64.84M | 72.13M | 95.79M | 128.53M | 165.44M | 162.08M | 221.73M | 281.08M | 255.43M |
Days Sales Outstanding | 121.34 | 117.41 | 127.46 | 167.72 | 217.05 | 190.86 | 121.52 | 131.73 | 116.14 | 100.25 |
Inventory | 37.73M | 40.5M | 48.16M | 60.8M | 81.69M | 105.36M | 111.2M | 136.78M | 143.07M | 143.47M |
Days Inventory Outstanding | 174.24 | 202.45 | 278.36 | 254.63 | 296.37 | 277.08 | 223.6 | 199.53 | 120.68 | 165.69 |
Other Current Assets | 2.78M | 4.52M | 4M | 0 | 3.67M | 21.41M | 25.42M | 18.01M | 43.38M | 37.01M |
Total Non-Current Assets | 280.53M | 277.73M | 269.09M | 290.87M | 449.82M | 415.83M | 384.61M | 756.01M | 687.26M | 674.89M |
Property, Plant & Equipment | 20.4M | 38.09M | 40.55M | 41.27M | 52.67M | 43.25M | 44.59M | 56.86M | 62.48M | 67.11M |
Fixed Asset Turnover | 8.67x | 5.29x | 5.09x | 5.05x | 4.10x | 7.32x | 10.92x | 10.80x | 14.14x | 14.64x |
Goodwill | 1.84M | 3.58M | 3.58M | 3.58M | 27.89M | 28.22M | 28.22M | 59.99M | 62.48M | 62.48M |
Intangible Assets | 229.79M | 201.6M | 180.39M | 188.51M | 294.12M | 251.63M | 209.01M | 541.83M | 479.53M | 467.16M |
Long-Term Investments | 800K | 5.02M | 0 | 5M | 5M | 0 | 6.2M | 0 | 0 | 0 |
Other Non-Current Assets | 5.04M | 1.47M | 6.25M | 802K | 2.21M | 11.36M | 5.87M | 12.22M | 13.71M | 11.57M |
Total Assets | 412.14M▲ 0% | 430.6M▲ 4.5% | 456.79M▲ 6.1% | 461.19M▲ 1.0% | 771.6M▲ 67.3% | 760.09M▼ 1.5% | 904.42M▲ 19.0% | 1.28B▲ 41.9% | 1.44B▲ 12.2% | 1.42B▲ 0% |
Asset Turnover | 0.43x | 0.47x | 0.45x | 0.45x | 0.28x | 0.42x | 0.54x | 0.48x | 0.61x | 0.66x |
Asset Growth % | 27.65% | 4.48% | 6.08% | 0.96% | 67.31% | -1.49% | 18.99% | 41.94% | 12.21% | 77.47% |
Total Current Liabilities | 39.23M | 165.55M | 61.68M | 78.56M | 87.54M | 99.44M | 145.48M | 193.68M | 278.11M | 239.51M |
Accounts Payable | 3.63M | 8.88M | 14.61M | 11.26M | 22.97M | 29.3M | 36.68M | 45.66M | 62.58M | 69.69M |
Days Payables Outstanding | 16.76 | 44.41 | 84.42 | 47.16 | 83.32 | 77.07 | 73.76 | 66.6 | 52.79 | 74.43 |
Short-Term Debt | 3.35M | 115.72M | 9.94M | 13.24M | 850K | 850K | 850K | 9.17M | 17.27M | 19.3M |
Deferred Revenue (Current) | 23.97M | 711K | 451K | 80K | 87K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29.94M | 31.69M | 20.33M | 33.39M | 44.27M | 43.71M | 65.73M | 77.03M | 198.26M | 150.52M |
Current Ratio | 3.35x | 0.92x | 3.04x | 2.17x | 3.68x | 3.46x | 3.57x | 2.72x | 2.71x | 3.12x |
Quick Ratio | 2.39x | 0.68x | 2.26x | 1.39x | 2.74x | 2.40x | 2.81x | 2.02x | 2.19x | 2.52x |
Cash Conversion Cycle | 278.81 | 275.45 | 321.41 | 375.19 | 430.1 | 390.87 | 271.36 | 264.66 | 184.03 | 191.51 |
Total Non-Current Liabilities | 198.15M | 67.79M | 182.32M | 186.93M | 325.32M | 322.11M | 301.35M | 661.49M | 621.54M | 620.16M |
Long-Term Debt | 198.15M | 67.3M | 175.81M | 172.44M | 286.52M | 285.67M | 284.82M | 614.92M | 307.93M | 308.47M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 7.59M | 9.49M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 496K | 6.51M | 14.48M | 38.8M | 36.44M | 16.53M | 46.57M | 313.61M | 311.69M |
Total Liabilities | 237.38M | 233.34M | 244M | 265.49M | 412.86M | 421.55M | 446.82M | 855.17M | 899.65M | 859.67M |
Total Debt | 201.51M | 183.01M | 185.75M | 185.69M | 287.37M | 286.52M | 285.67M | 624.09M | 325.19M | 327.76M |
Net Debt | 170.36M | 140.01M | 123.42M | 177.82M | 187.07M | 238.29M | 64.55M | 479.23M | 39.61M | 16.59M |
Debt / Equity | 1.15x | 0.93x | 0.87x | 0.95x | 0.80x | 0.85x | 0.62x | 1.46x | 0.60x | 0.58x |
Debt / EBITDA | 3.58x | 2.65x | 3.05x | 6.49x | 38.53x | 11.76x | 2.68x | 9.14x | 1.88x | 1.54x |
Net Debt / EBITDA | 3.03x | 2.03x | 2.02x | 6.21x | 25.08x | 9.78x | 0.60x | 7.02x | 0.23x | 0.08x |
Interest Coverage | 2.43x | 2.36x | 1.24x | -1.75x | -3.70x | -1.23x | 1.74x | -0.26x | 5.78x | 4.61x |
Total Equity | 174.76M▲ 0% | 197.26M▲ 12.9% | 212.79M▲ 7.9% | 195.7M▼ 8.0% | 358.74M▲ 83.3% | 338.54M▼ 5.6% | 457.6M▲ 35.2% | 428.53M▼ 6.4% | 540.72M▲ 26.2% | 562.3M▲ 0% |
Equity Growth % | 3.01% | 12.88% | 7.87% | -8.03% | 83.31% | -5.63% | 35.17% | -6.35% | 26.18% | 66.44% |
Book Value per Share | 15.13 | 16.76 | 17.67 | 16.36 | 28.48 | 20.82 | 25.15 | 22.18 | 25.47 | 26.10 |
Total Shareholders' Equity | 174.76M | 197.26M | 212.79M | 195.7M | 358.74M | 338.54M | 457.6M | 428.53M | 540.72M | 562.3M |
Common Stock | 1K | 1K | 1K | 1K | 1K | 1K | 2K | 2K | 3K | 3K |
Retained Earnings | -4.01M | 11.49M | 17.58M | -4.97M | -47.77M | -97.29M | -80.13M | -100.28M | -23.1M | 6.39M |
Treasury Stock | -259K | -659K | -723K | -2.25M | -3.13M | -5.09M | -10.08M | -21.04M | 0 | 0 |
Accumulated OCI | -6.59M | -379K | -4.87M | -11.44M | -3.06M | 12.17M | 8.86M | 5.34M | 1.03M | 479K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANIP Cash Flow Statement
ANI Pharmaceuticals, Inc. (ANIP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 39.42M | 67.07M | 45.63M | 15.27M | 3.32M | -31.2M | 118.96M | 64.02M | 185.22M | 208.61M |
Operating CF Margin % | 22.29% | 33.27% | 22.09% | 7.32% | 1.54% | -9.86% | 24.44% | 10.42% | 20.97% | - |
Operating CF Growth % | 43.49% | 70.16% | -31.97% | -66.54% | -78.24% | -1039.28% | 481.24% | -46.19% | 189.34% | 746.82% |
Net Income | -1.08M | 15.49M | 6.09M | -22.55M | -42.6M | -47.9M | 18.78M | -18.52M | 78.34M | 89.67M |
Depreciation & Amortization | 27.93M | 33.74M | 44.61M | 44.64M | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M | 89.44M |
Stock-Based Compensation | 6.09M | 6.78M | 9.22M | 12.94M | 10.49M | 14.6M | 20.65M | 29.34M | 37.93M | 29.06M |
Deferred Taxes | 3.56M | -5.18M | -9.13M | -13.21M | -16.75M | -15.25M | -11.74M | -21.91M | 14.24M | 20.14M |
Other Non-Cash Items | 8.57M | 10.27M | 9.42M | 6.07M | 5.02M | 8.99M | 6.62M | 18.56M | -29.57M | -12.05M |
Working Capital Changes | -5.65M | 5.97M | -14.58M | -12.63M | -84K | -51.3M | 24.86M | -11.19M | -7.12M | -8.07M |
Change in Receivables | -12.89M | -4.74M | -7.29M | -23.66M | -5.55M | -36.91M | 3.36M | -21.09M | -58.53M | -34.78M |
Change in Inventory | 5.36M | -379K | -7.66M | -2.76M | 3.22M | -23.63M | -5.84M | -21.29M | -5.96M | -5.77M |
Change in Payables | 3K | 3.47M | 5.04M | -2.29M | 10.17M | 5.04M | 7.55M | 479K | 15.16M | 14.96M |
Cash from Investing | -107.99M | -27.38M | -27.55M | -68.32M | -105.48M | -15.74M | -18.51M | -404.72M | -34.32M | -25.8M |
Capital Expenditures | -107.99M | -10.91M | -27.55M | -6.13M | -2.56M | -8.88M | -8.87M | -16.24M | -34.32M | -30.82M |
CapEx % of Revenue | 61.07% | 5.41% | 13.34% | 2.94% | 1.18% | 2.81% | 1.82% | 2.64% | 3.89% | 3.34% |
Acquisitions | 0 | -16.47M | 0 | 0 | -84.49M | -33K | 0 | -401.28M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -97.62M | -5.17M | 0 | -62.19M | -18.43M | -6.83M | -9.64M | 12.8M | 0 | 5.03M |
Cash from Financing | 72.36M | -27.82M | 1.25M | -1.44M | 194.59M | -5.13M | 67.44M | 264.94M | -9.94M | -21.65M |
Debt Issued (Net) | 75M | -2.81M | 115.29M | -534K | 99.02M | -3M | -3M | 345.22M | -10.16M | -12.19M |
Equity Issued (Net) | -259K | -659K | 4.71M | -1.52M | 93.69M | -1.96M | 75.57M | -10.96M | 1.4M | -18.13M |
Dividends Paid | 0 | 0 | 0 | 0 | -190K | -1.63M | -1.63M | -1.63M | -1.16M | -751K |
Share Repurchases | -259K | -659K | -1.03M | -1.52M | -890K | -1.96M | -4.99M | -10.96M | -12.21M | -20.37M |
Other Financing | -2.38M | -24.34M | -118.75M | 618K | 2.07M | 1.46M | -3.5M | -67.69M | -26K | 9.41M |
Net Change in Cash | 3.78M▲ 0% | 11.88M▲ 214.0% | 19.33M▲ 62.7% | -54.49M▼ 381.9% | 92.43M▲ 269.6% | -52.07M▼ 156.3% | 167.89M▲ 422.4% | -76.23M▼ 145.4% | 140.73M▲ 284.6% | 161.38M▲ 0% |
Free Cash Flow | -68.57M▲ 0% | 56.16M▲ 181.9% | 18.08M▼ 67.8% | -53.05M▼ 393.4% | -20.32M▲ 61.7% | -47.66M▼ 134.6% | 100.45M▲ 310.8% | 47.06M▼ 53.1% | 171.39M▲ 264.2% | 165.6M▲ 0% |
FCF Margin % | -38.78% | 27.86% | 8.75% | -25.45% | -9.4% | -15.06% | 20.63% | 7.66% | 19.4% | 17.93% |
FCF Growth % | 43.6% | 181.9% | -67.8% | -393.41% | 61.71% | -134.58% | 310.77% | -53.15% | 264.16% | 236.92% |
FCF per Share | -5.94 | 4.77 | 1.50 | -4.43 | -1.61 | -2.93 | 5.52 | 2.44 | 8.07 | 7.69 |
FCF Conversion (FCF/Net Income) | -36.63x | 4.33x | 7.49x | -0.68x | -0.08x | 0.65x | 6.33x | -3.46x | 2.36x | 1.85x |
Interest Paid | 3.76M | 6.29M | 6.09M | 6.93M | 9.71M | 21.48M | 31.43M | 24.38M | 26.93M | 13.42M |
Taxes Paid | 17.79M | 6.4M | 10.03M | 4.98M | 10.37M | 288K | 1.23M | 19.06M | 17.67M | 16.33M |
ANIP Key Ratios
ANI Pharmaceuticals, Inc. (ANIP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -0.62% | 8.33% | 2.97% | -11.04% | -15.37% | -13.74% | 4.72% | -4.18% | 16.16% | 17.32% |
Return on Invested Capital (ROIC) | 6.99% | 7.77% | 3.64% | -3.38% | -6.49% | -4.71% | 6.41% | 0.06% | 8.19% | 14.31% |
Gross Margin | 55.31% | 63.77% | 69.42% | 58.19% | 53.45% | 56.13% | 62.71% | 59.27% | 51.01% | 65.94% |
Net Margin | -0.61% | 7.69% | 2.95% | -10.82% | -19.71% | -15.14% | 3.86% | -3.01% | 8.87% | 9.71% |
Debt / Equity | 1.15x | 0.93x | 0.87x | 0.95x | 0.80x | 0.85x | 0.62x | 1.46x | 0.60x | 0.58x |
Interest Coverage | 2.43x | 2.36x | 1.24x | -1.75x | -3.70x | -1.23x | 1.74x | -0.26x | 5.78x | 4.61x |
FCF Conversion | -36.63x | 4.33x | 7.49x | -0.68x | -0.08x | 0.65x | 6.33x | -3.46x | 2.36x | 1.85x |
Revenue Growth | 37.49% | 13.99% | 2.47% | 0.93% | 3.67% | 46.38% | 53.87% | 26.2% | 43.78% | 37.03% |
Related:ANIP Dividend History·ANIP Revenue History·ANIP Price History·ANIP P/E History·ANIP Financial Ratios·ANIP Institutional Holders
ANIP SEC Filings & Documents
ANI Pharmaceuticals, Inc. (ANIP) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANIP Frequently Asked Questions
ANI Pharmaceuticals, Inc. (ANIP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ANI Pharmaceuticals, Inc. (ANIP) reported $923.7M in revenue for fiscal year 2025. This represents a 750508% increase from $0.1M in 1998.
ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 43.8% over the past year. This is strong growth.
Yes, ANI Pharmaceuticals, Inc. (ANIP) is profitable, generating $89.7M in net income for fiscal year 2025 (8.9% net margin).
Dividend & Returns
ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
ANI Pharmaceuticals, Inc. (ANIP) has a return on equity (ROE) of 16.2%. This is reasonable for most industries.
ANI Pharmaceuticals, Inc. (ANIP) generated $165.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.